COVID-19 Drug Treatment in China

PURPOSE OF REVIEW: An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Linzi, Jiang, Shuang, Yang, Xinrong, Wang, Zhibin, Yang, Chunjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Hot Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302922/
https://www.ncbi.nlm.nih.gov/pubmed/32837851
http://dx.doi.org/10.1007/s40495-020-00218-5
_version_ 1783547951322234880
author Fan, Linzi
Jiang, Shuang
Yang, Xinrong
Wang, Zhibin
Yang, Chunjuan
author_facet Fan, Linzi
Jiang, Shuang
Yang, Xinrong
Wang, Zhibin
Yang, Chunjuan
author_sort Fan, Linzi
collection PubMed
description PURPOSE OF REVIEW: An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19. RECENT FINDINGS: At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress. SUMMARY: In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19.
format Online
Article
Text
id pubmed-7302922
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73029222020-06-19 COVID-19 Drug Treatment in China Fan, Linzi Jiang, Shuang Yang, Xinrong Wang, Zhibin Yang, Chunjuan Curr Pharmacol Rep Hot Topic PURPOSE OF REVIEW: An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19. RECENT FINDINGS: At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress. SUMMARY: In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19. Springer International Publishing 2020-09-07 2020 /pmc/articles/PMC7302922/ /pubmed/32837851 http://dx.doi.org/10.1007/s40495-020-00218-5 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Hot Topic
Fan, Linzi
Jiang, Shuang
Yang, Xinrong
Wang, Zhibin
Yang, Chunjuan
COVID-19 Drug Treatment in China
title COVID-19 Drug Treatment in China
title_full COVID-19 Drug Treatment in China
title_fullStr COVID-19 Drug Treatment in China
title_full_unstemmed COVID-19 Drug Treatment in China
title_short COVID-19 Drug Treatment in China
title_sort covid-19 drug treatment in china
topic Hot Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302922/
https://www.ncbi.nlm.nih.gov/pubmed/32837851
http://dx.doi.org/10.1007/s40495-020-00218-5
work_keys_str_mv AT fanlinzi covid19drugtreatmentinchina
AT jiangshuang covid19drugtreatmentinchina
AT yangxinrong covid19drugtreatmentinchina
AT wangzhibin covid19drugtreatmentinchina
AT yangchunjuan covid19drugtreatmentinchina

Ejemplares similares